[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
[ Mon, Mar 11th 2024 ]: WOPRAI
Swayampakula Ramakanth Maintained (ALXO) at Strong Buy with Increased Target to $20 on, Mar 11th, 2024
- 🞛 This publication is a summary or evaluation of another publication
Swayampakula Ramakanth of HC Wainwright & Co., Maintained "ALX Oncology Holdings Inc." (ALXO) at Strong Buy with Increased Target from $18 to $20 on, Mar 11th, 2024.
Swayampakula has made no other calls on ALXO in the last 4 months.
There are 3 other peers that have a rating on ALXO. Out of the 3 peers that are also analyzing ALXO, 1 agrees with Swayampakula's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Bradley Canino of "Stifel" Downgraded from Strong Buy to Hold and Increased Target to $14 on, Friday, March 8th, 2024
These are the ratings of the 2 analyists that currently disagree with Swayampakula
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $21 on, Friday, March 8th, 2024
- Michael Yee of "Jefferies" Upgraded from Hold to Strong Buy and Increased Target to $18 on, Friday, December 8th, 2023